Key facts
- It has raised $14.0M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Qianhai FoF, Tianjin Venture Capital, CASH Capital, Wuxi Xingyuan Private Equity Fund Management, Gaolin Capital — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tmaxtree
- ·The full record, as it builds
Funding rounds
No funding rounds for Tmaxtree are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tmaxtree
Manufacturer of biotechnology equipment intended to advance microbial breeding and genetic research. The company offers plasma mutagenesis instruments, single-cell microdroplet sorters, continuous evolution culture devices, and automated screening platforms, enabling research institutes and industrial biotechnology enterprises to enhance strain improvement efficiency and innovation capacity.
- Sector
- Healthcare
- HQ
- Luoyang, China
- Founded
- 2014
- Employees
- 34
- Website
- tmaxtree.com/
- Ownership
- Privately Held (backing)
Tmaxtree doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tmaxtree shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tmaxtree in its N-PORT filings yet. We sweep new filings monthly.